272. 進行性骨化性線維異形成症 Fibrodysplasia ossificans progressiva Clinical trials / Disease details


臨床試験数 : 39 薬物数 : 38 - (DrugBank : 7) / 標的遺伝子数 : 27 - 標的パスウェイ数 : 95

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-002541-29-IT
(EUCTR)
15/03/201826/01/2021A clinical trial to evaluate the Efficacy and Safety of Oral Palovarotene as a treatment for Fibrodysplasia Ossificans Progressiva (FOP)A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) - MOVE Trial Fibrodysplasia Ossificans Progressiva (FOP)
MedDRA version: 20.0;Level: PT;Classification code 10068715;Term: Fibrodysplasia ossificans progressiva;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: not applicable
Product Name: PALOVAROTENE
Product Code: not assigned
INN or Proposed INN: Palovarotene
Other descriptive name: PALOVAROTENE
Trade Name: not applicable
Product Name: PALOVAROTENE 1.5 mg
Product Code: [not applicable]
INN or Proposed INN: PALOVAROTENE
Other descriptive name: Palovarotene
Trade Name: not applicable
Product Name: PALOVAROTENE-2 mg
Product Code: [not assigned]
INN or Proposed INN: PALOVAROTENE
Other descriptive name: Palovarotene
Trade Name: not applicable
Product Name: PALOVAROTENE
Product Code: [not applicable]
INN or Proposed INN: PALOVAROTENE
Other descriptive name: palovarotene
Trade Name: not applicable
Product Name: PALOVAROTENE-3 mg
Product Code: [not applicable]
INN or Proposed INN: PALOVAROTENE
Other descriptive name: Palovarotene
Trade Name: not applicable
Product Name: PALOVAROTENE-4 mg
CLEMENTIA PHARMACEUTICALS INC.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
107Phase 3United States;Spain;Korea, Democratic People's Republic of;Russian Federation;United Kingdom;Italy;France;Canada;Argentina;Brazil;Australia;South Africa;Netherlands;Germany;Japan;Sweden;Korea, Republic of